Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Combinatorial Effects of Chrysin with Doxorubicin, 5-Fluorouracil, and Cyclophosphamide on Triple-Negative Breast Cancer Cell Line
  6. Crossref

IJ Pharmaceutical Research

Home
Current IssueAll IssuesIn PressAccepted Manuscripts
SearchInstructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Crossref


1. Functionalized Core/Shell Gold-Palladium Bimetallic Nanoparticles in Transferrin-Targeted Dual-Drug Delivery in a Cervical Cancer Cell Model

- Lorenzo Lance David

- Moganavelli Singh

2. Protective effect of chrysin on di (2-ethylhexyl) phthalate-induced toxicity in mice testis: An experimental study

- Zahra Matin Manesh

- Hossein Zeinali

- Fatemeh Ghanbari

- Afsaneh Mafi

- Mehdi Goudarzi

- Mahdiieh Ghoddoosi

- Saeed Hajihashemi

- Hamid Heidari

3. The Effect of Two Types of Aerobic Exercise on the Regulation of Mechanisms Related to DNA Damage and Cell Death in the Hearts of Doxorubicin-Treated Mice

- Asieh Sadat Mousavian

- Gholamhasan Jafarzadeh

- Hassan Darvakh

- Asma Taheri

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.